<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1577">
  <stage>Registered</stage>
  <submitdate>30/05/2007</submitdate>
  <approvaldate>30/05/2007</approvaldate>
  <nctid>NCT00481091</nctid>
  <trial_identification>
    <studytitle>A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia</studytitle>
    <scientifictitle>A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2007-002143-25</secondaryid>
    <secondaryid>M06-873</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Lymphocytic Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-263

Experimental: Arm NA, Group is Applicable - Group/Cohort Number or Label is numerical and sequential starting with dose level 1


Treatment: drugs: ABT-263
Phase 1 dosing under two different schedules: 14 days on drug, 7 days or (14/21) or continuous dosing.
Phase 2a dosing at the recommended phase 2a dose and schedule

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD)</outcome>
      <timepoint>14 days on therapy and 7 days off therapy OR 21 days continuous dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile evaluation</outcome>
      <timepoint>Repeating sequence of 14 days on therapy and 7 days off therapy OR 21 days of continuous dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Preliminary efficacy assessment (Phase 2a)</outcome>
      <timepoint>Repeating cycles of 21 days continuous dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessment</outcome>
      <timepoint>Repeating sequence of 14 days on therapy and 7 days off therapy OR 21 days of continuous dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Relapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion
             of investigator

          -  Eastern Cooperative Oncology Group (ECOG) &lt;= 1

          -  Adequate bone marrow independent of growth factor support, renal and hepatic function
             per defined laboratory criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History or clinically suspicious for cancer-related Central Nervous System disease

          -  Receipt of allogenic or autologous stem cell transplant

          -  Recent history (within 1 year of first dose) of underlying, predisposing condition of
             bleeding or currently exhibits signs of bleeding

          -  Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis

          -  Active immune thrombocytopenic purpura or history of being refractory to platelet
             transfusions (within 1 year of first dose)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>25/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>72</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Peter MacCallum Cancer Centre /ID# 6583 - East Melbourne</hospital>
    <hospital>Royal Melbourne Hospital /ID# 5576 - Parkville, Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3050 - Parkville, Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie (prior sponsor, Abbott)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Genentech, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of
      ABT-263 under two different dosing schedules with the objective of defining the dose limiting
      toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263
      at the defined recommended Phase 2 dose to obtain additional safety information and a
      preliminary assessment of efficacy. The Extension Study portion will allow active subjects to
      continue to receive ABT-263 for up to 7 years after the last subject transitions with less
      frequent study evaluations.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00481091</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mack Mabry, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>